EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial



A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial



Annals of Oncology 24(9): 2284-2291



In a retrospective study on node-negative breast cancer, a prognostic index consisting of a proliferation factor, S-phase fraction (SPF), progesterone receptor status (PR), and tumour size identified one-third of patients as high risk, with a sixfold increased risk of breast cancer death. This prospective multicenter cohort study was set up to validate the index. and methodsIn 576 T1-2N0 patients <60 years, prospective analyses of PR and SPF were carried out. High risk was defined as ≥2 of the following: size >20 mm, PR-negativity, and high SPF (in the absence of SPF, Bloom–Richardson grade 3). Median follow-up was 17.8 years. Thirty-one percent were high risk. In univariate analysis, the index was prognostic for breast cancer-specific survival after 5 years [hazard ratio (HR) = 4.7, 95% confidence interval (95% CI) 2.5–8.9], 10 years (HR = 2.2, 95% CI 1.5–3.3), and 15 years (HR = 1.7, 95% CI 1.2–2.5), and remained significant after adjustment for adjuvant medical treatment and age. In the 37% of patients with no risk factors, only one patient died of breast cancer the first 5 years. This prospective study validates a prognostic index consisting of a proliferation factor, PR-status, and tumour size. The index may be helpful for prognostic considerations and for selection of patients in need of adjuvant therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 036906274

Download citation: RISBibTeXText

PMID: 23704202

DOI: 10.1093/annonc/mdt186



Related references

S-phase fraction and menopausal status as the most important prognostic factors of disease-free survival for node negative patients with breast cancer. A prospective study. Polish Journal of Pathology 54(2): 101-110, 2003

Long-term prognostic impact of risk classifications in node-negative breast cancer comparison between Adjuvant!, St. Gallen, and a novel risk algorithm used in the prospectively randomized Node-Negative-Breast-Cancer-3 trial (NNBC-3). European Journal of Cancer Supplements 6(7): 194-195, 2008

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Annals of Oncology 20(2): 258-264, 2008

Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. Journal of Clinical Oncology 23(25): 5993-6001, 2005

Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients-A status report of the prospective clinical trial NNBC 3-Europe. Journal of Clinical Oncology 24(18_suppl): 10503-10503, 2016

Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors. Oncology Letters 17(1): 616-622, 2019

Impact of DNA image cytometry (ICM) parameter and established prognostic factors on disease free survival (DFS) and overall survival (OS) of node-negative breast cancer (NNBC) patients. Zentralblatt für Gynakologie 125(9): 368-374, 2003

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. Journal of Clinical Oncology 19(7): 2010-2019, 2001

Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study. Breast Cancer Research 8(4): R44-R44, 2006

Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Clinical Breast Cancer 17(1): 41-47, 2016

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for tumor-biological risk assessment in node-negative breast cancer patients The multicenter trial NNBC 3-Europe. European Journal of Cancer Supplements 6(7): 188-189, 2008

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 118(13): 3236-3243, 2012

Validation of the Tenon breast cancer score for predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis: a prospective multicenter study. Breast Cancer Research and Treatment 113(3): 537-543, 2008

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet. Oncology 11(10): 927-933, 2010

Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer. Zhonghua Wai Ke Za Zhi 35(8): 475-477, 1997